AI assistant
Sanofi — Capital/Financing Update 2009
May 6, 2009
1643_rns_2009-05-06_513e1dfb-aa1d-4a0e-98d1-af2525622740.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFERING OF SECURITIES IN THE UNITED STATES OF AMERICA. THE NOTES MAY NOT BE OFFERED, SOLD OR DELIVERED IN THE UNITED STATES OF AMERICA, EXCEPT PURSUANT TO A REGISTRATION OR AN EXEMPTION FROM REGISTRATION REQUIREMENTS UNDER OR PURSUANT TO THE U.S. SECURITIES ACT OF 1933, AS AMENDED. SANOFI-AVENTIS DOES NOT INTEND TO REGISTER THE PROPOSED OFFERING IN WHOLE OR IN PART IN THE UNITED STATES OF AMERICA OR TO CONDUCT A PUBLIC OFFERING IN THE UNITED STATES OF AMERICA.
Sanofi-aventis has successfully completed the placement of a 4-year and a 7-year Euro notes issue for an aggregate principal amount of EUR 3 billion
Paris, France – May 6th, 2009 - Sanofi-aventis (EURONEXT:SAN and NYSE: SNY) - rated AA- by Standard & Poor's and A1 by Moody's - has successfully completed the placement of a 4-year and a 7-year Euro notes issue with the following principal terms:
4-year Notes:
Principal Amount: 1.5 billion Euros Coupon: 3.5% Issue Price: 99.923% Maturity: May 18th, 2013
7-year Notes:
Principal Amount: 1.5 billion Euros Coupon: 4.5% Issue Price: 99.641% Maturity: May 18th, 2016
These two issues are made under the Company's Euro Medium Term Note Programme.
Applications for subscription have exceeded 20 billion Euros. The very positive response to these offerings confirms the confidence of debt investors in the prospects of the group.
*** This document is an advertisement and not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of November 4th, 2003 (as implemented in each Member State of the European Economic Area (the "Member States"), the ("Prospectus Directive")).
No action has been or will be undertaken to make an offer to the public of the notes described above (the "Notes").
The Base Prospectus dated March 30, 2009 relating to the Programme has been approved by the Commission de Surveillance du Secteur Financier in Luxembourg. This prospectus has not been and will not be passported in another Member State in relation to the above mentioned issues pursuant to the Prospectus Directive.
This press release may only be communicated to persons in the United Kingdom in circumstances where section 21(1) of the Financial Services and Markets Act 2000 does not apply.
Sanofi-aventis: www.sanofi-aventis.com Media Relations: Tél. : (+) 33 1 53 77 44 50 - E-mail : [email protected] Investor Relations : Tél. : (+) 33 1 53 77 45 45 - E-mail : [email protected]